Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.

Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan T, Huang J, Davicioni E, An SS, Riddle RC, Thorek DLJ, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ.

Cancer Res. 2019 Jul 15;79(14):3636-3650. doi: 10.1158/0008-5472.CAN-18-2931. Epub 2019 May 23.

PMID:
31123087
2.

If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, Zheng Q, Bieberich CJ, Haffner MC, De Marzo AM.

Asian J Urol. 2019 Jan;6(1):10-25. doi: 10.1016/j.ajur.2018.11.006. Epub 2018 Dec 12. Review.

3.

Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma.

Gallia GL, Zhang M, Ning Y, Haffner MC, Batista D, Binder ZA, Bishop JA, Hann CL, Hruban RH, Ishii M, Klein AP, Reh DD, Rooper LM, Salmasi V, Tamargo RJ, Wang Q, Williamson T, Zhao T, Zou Y, Meeker AK, Agrawal N, Vogelstein B, Kinzler KW, Papadopoulos N, Bettegowda C.

Nat Commun. 2018 Dec 21;9(1):5410. doi: 10.1038/s41467-018-07578-z.

4.

CD38 is methylated in prostate cancer and regulates extracellular NAD.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, Teitell MA, Goldstein AS.

Cancer Metab. 2018 Sep 21;6:13. doi: 10.1186/s40170-018-0186-3. eCollection 2018.

5.

Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors.

Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich ML, Netto GJ, Matoso A, Nirschl TR, Zheng Q, Hicks JL, Nelson WG, De Marzo AM, Marchionni L, Drake CG, Yegnasubramanian S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8580-E8582. doi: 10.1073/pnas.1803292115. Epub 2018 Sep 4. No abstract available.

6.

Malignant Peripheral Nerve Sheath Tumors Show Decreased Global DNA Methylation.

Nix JS, Haffner MC, Ahsan S, Hicks J, De Marzo AM, Blakeley J, Raabe EH, Rodriguez FJ.

J Neuropathol Exp Neurol. 2018 Oct 1;77(10):958-963. doi: 10.1093/jnen/nly076.

PMID:
30169729
7.

Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM.

Cold Spring Harb Perspect Med. 2019 Apr 1;9(4). pii: a030403. doi: 10.1101/cshperspect.a030403. Review.

PMID:
30082453
8.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

9.

PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.

Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G.

Am J Surg Pathol. 2018 Oct;42(10):1384-1389. doi: 10.1097/PAS.0000000000001105.

PMID:
29901568
10.

The structure of the nucleus in normal and neoplastic prostate cells: untangling the role of type 2 DNA topoisomerases.

Nelson WG, Haffner MC, Yegnasubramanian S.

Am J Clin Exp Urol. 2018 Apr 1;6(2):107-113. eCollection 2018. Review.

11.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

12.

Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.

Höti N, Yang S, Hu Y, Shah P, Haffner MC, Zhang H.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):137-146. doi: 10.1038/s41391-017-0016-7. Epub 2018 Jan 16.

13.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

14.

Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto GJ, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL.

Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26.

15.

Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.

Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):28-35. doi: 10.1038/pcan.2016.49. Epub 2016 Nov 1.

16.

Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer.

Guedes LB, Morais CL, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL.

Clin Cancer Res. 2016 Sep 15;22(18):4651-63. doi: 10.1158/1078-0432.CCR-16-0205. Epub 2016 May 10.

17.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

18.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.

19.

Premalignancy in Prostate Cancer: Rethinking What we Know.

De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG.

Cancer Prev Res (Phila). 2016 Aug;9(8):648-56. doi: 10.1158/1940-6207.CAPR-15-0431. Epub 2016 Jan 26. Review.

20.

Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies.

Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, Netto GJ, Haffner MC.

PLoS One. 2016 Jan 19;11(1):e0146302. doi: 10.1371/journal.pone.0146302. eCollection 2016.

21.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia.

Haffner MC, Barbieri CE.

Eur Urol. 2016 May;69(5):831-3. doi: 10.1016/j.eururo.2015.11.020. Epub 2015 Dec 2. No abstract available.

PMID:
26651925
22.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

23.

The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.

Abdollah F, Dalela D, Haffner MC, Culig Z, Schalken J.

Eur Urol Focus. 2015 Sep;1(2):99-108. doi: 10.1016/j.euf.2015.08.001. Epub 2015 Aug 28. Review.

PMID:
28723439
24.

Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Hurley PJ, Hughes RM, Simons BW, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An SS, Schaeffer EM.

Cancer Res. 2015 Oct 15;75(20):4322-34. doi: 10.1158/0008-5472.CAN-15-0024. Epub 2015 Aug 20.

25.

Should Gleason 6 be labeled as cancer?

Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM.

Curr Opin Urol. 2015 May;25(3):238-45. doi: 10.1097/MOU.0000000000000165. Review.

26.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.

Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.

27.

Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.

Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL.

Mod Pathol. 2015 Mar;28(3):446-56. doi: 10.1038/modpathol.2014.115. Epub 2014 Sep 12.

28.

Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.

Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, Ballester LY, Nazarian J, Eberhart CG, Rodriguez FJ.

Acta Neuropathol Commun. 2014 Jun 3;2:59. doi: 10.1186/2051-5960-2-59.

29.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

30.

Diagnostic challenges of clonal heterogeneity in prostate cancer.

Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB.

J Clin Oncol. 2015 Mar 1;33(7):e38-40. doi: 10.1200/JCO.2013.50.3540. Epub 2014 Mar 17. No abstract available.

PMID:
24638011
31.

Tracking the clonal origin of lethal prostate cancer.

Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Clin Invest. 2013 Nov;123(11):4918-22. doi: 10.1172/JCI70354. Epub 2013 Oct 25.

32.

Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease.

Haffner MC, Pellakuru LG, Ghosh S, Lotan TL, Nelson WG, De Marzo AM, Yegnasubramanian S.

Cell Cycle. 2013 Jun 15;12(12):1835-41. doi: 10.4161/cc.25010. Epub 2013 May 15.

33.

Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.

Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, Nelson WG, Jones RJ, Yegnasubramanian S.

Oncotarget. 2013 May;4(5):715-28.

34.

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8. Epub 2013 Apr 2.

35.

Combining routine morphology, p16(INK4a) immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: a tissue microarray study using classifier performance analyses.

Chaux A, Cubilla AL, Haffner MC, Lecksell KL, Sharma R, Burnett AL, Netto GJ.

Urol Oncol. 2014 Feb;32(2):171-7. doi: 10.1016/j.urolonc.2012.04.017. Epub 2013 Mar 14.

PMID:
23499169
36.

Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.

Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Pathol. 2013 Jun;230(2):174-83. doi: 10.1002/path.4186.

37.

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.

Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S.

Sci Transl Med. 2013 Jan 23;5(169):169ra10. doi: 10.1126/scitranslmed.3005211.

38.

Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.

Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG.

PLoS One. 2012;7(7):e41036. doi: 10.1371/journal.pone.0041036. Epub 2012 Jul 19.

39.

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.

Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, Kronberger IE, Laimer K, Gurel B, Koller JB, Seifarth C, Zelger B, Klocker H, Rasse M, Doppler W, Bander NH.

Mod Pathol. 2012 Aug;25(8):1079-85. doi: 10.1038/modpathol.2012.66. Epub 2012 Mar 30.

40.

Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers.

Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S.

Oncotarget. 2011 Aug;2(8):627-37.

41.

Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.

Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ.

Mod Pathol. 2011 Nov;24(11):1511-20. doi: 10.1038/modpathol.2011.111. Epub 2011 Jul 8.

42.

Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.

Nelson WG, Haffner MC, Yegnasubramanian S.

Cancer Cell. 2011 Jul 12;20(1):7-9. doi: 10.1016/j.ccr.2011.06.019.

43.

Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences.

Yegnasubramanian S, Wu Z, Haffner MC, Esopi D, Aryee MJ, Badrinath R, He TL, Morgan JD, Carvalho B, Zheng Q, De Marzo AM, Irizarry RA, Nelson WG.

BMC Genomics. 2011 Jun 13;12:313. doi: 10.1186/1471-2164-12-313.

44.

Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target?

Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S.

Clin Cancer Res. 2011 Jun 15;17(12):3858-64. doi: 10.1158/1078-0432.CCR-10-2044. Epub 2011 Mar 8.

45.

ERG gene rearrangements are common in prostatic small cell carcinomas.

Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ.

Mod Pathol. 2011 Jun;24(6):820-8. doi: 10.1038/modpathol.2011.7. Epub 2011 Feb 18.

46.

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A.

Cancer Biol Ther. 2010 Nov 15;10(10):1009-18. doi: 10.4161/cbt.10.10.13248. Epub 2010 Nov 15.

47.

Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.

Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA.

Prostate. 2011 Mar 1;71(4):333-43. doi: 10.1002/pros.21247. Epub 2010 Aug 31.

48.

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.

Nat Genet. 2010 Aug;42(8):668-75. doi: 10.1038/ng.613. Epub 2010 Jul 4.

49.

Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer.

Mühlmann G, Untergasser G, Zitt M, Zitt M, Maier H, Mikuz G, Kronberger IE, Haffner MC, Gunsilius E, Ofner D.

Virchows Arch. 2010 Jun;456(6):635-46. doi: 10.1007/s00428-010-0926-4. Epub 2010 May 15.

PMID:
20473620
50.

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.

Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH.

Hum Pathol. 2009 Dec;40(12):1754-61. doi: 10.1016/j.humpath.2009.06.003. Epub 2009 Aug 27.

PMID:
19716160

Supplemental Content

Loading ...
Support Center